Repligen Corporation
RGENHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeRepligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company carries a $9.46B market cap, placing it firmly in the mid-cap category. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Market Cap
$9.46B
Beta
1.05
P/E (TTM)
226.49
P/E (Fwd)
63.54
EPS (TTM)
$0.74
EPS (Fwd)
$2.64
ROE
2.0%
ROA
1.4%
Cash
$810.4M
Total Debt
$690.9M
Free CF
$113.4M
52W Change
41.2%
Annual Financials
Cash vs Debt
Where RGEN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RGEN finished 28.53% above its 150-day moving average ($134.55) and 21.96% above its 200-day moving average ($141.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RGEN overbought or oversold?
At the September 3, 2026 close, RGEN's RSI(14) was 55.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Repligen Corporation holds $810.4M in cash against $690.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $113.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 2.0%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.4% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $670.5M to $738.3M.
At over 50x earnings, RGEN carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RGEN.